Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Biweekly Gemcitabine Combinations in Metastatic Breast Cancer
NCT00191854Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Mar 2005
- Primary completion
- Aug 2008
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 2, randomised, open-label trial of gemcitabine in breast cancer (3 arms), sponsored by Eli Lilly and Company. Primary endpoint: Best Overall Response up to 24 months. Started Mar 2005; status: completed.
02
Drugs
gemcitabine
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00191854.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00191854.